Ute Hennrich

Years Active: 2019-2022
Publications (10 Years): 5

Deutsches Krebsforschungszentrum

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Deutsches Krebsforschungszentrum Nov 01 2008

Germany

Senior Scientist :: Division of Radiopharmaceutical Chemistry

Publications

Ute Hennrich, Matthias Eder
[ 177 Lu]Lu-PSMA-617 (Pluvicto TM ): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel, Switzerland) 15 (10) (2022)
Ute Hennrich, Matthias Eder
[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals (Basel, Switzerland) 14 (8) (2021)
Ines Katzschmann, Heike Marx, Klaus Kopka, Ute Hennrich
Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer. Pharmaceuticals (Basel, Switzerland) 14 (3) (2021)
Ute Hennrich, Martina Benešová
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals (Basel, Switzerland) 13 (3) (2020)
Ute Hennrich, Klaus Kopka
Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals (Basel, Switzerland) 12 (3) (2019)

Ute Hennrich.css-eqlu8i{font-size:small;padding-left:4px;}